Project Details
Description
Project Summary
Pancreatic beta cells derived from human induced pluripotent stem cells (hiPSCs) hold the potential to
dramatically change the treatment of type 1 diabetes (T1D). To realize the therapeutic application of these
cells, however, we need to develop a robust and rapid means for generating beta cells. Here, the investigators
propose a novel paradigm for direct programming of hiPSC into beta cells via CRISPR activation of
transcription factors (TFs). These CRISPR activation effectors will be delivered into hiPSCs using modRNAs,
avoiding genomic integrations by previous viral vector approach. Furthermore, the investigators will also use
recent advances in gene editing to generate universal donor hiPSC clones, which will be used for beta cell
programming. These universal donor beta cells can be used for allogeneic transplantation without immune
rejections.
First, the investigators will investigate optimal msgRNAs for activation of pancreatic TFs in hiPSCs. Next, they
will use a multiplexed msgRNA expression system to express all msgRNAs to activate numerous msgRNAs
coupled with the dCas9 activator modRNA to study beta cell programming. In Aim 3, the investigators will
generate immune-privileged beta cells via programming of universal donor hiPSCs. Universal donor hiPSCs
will be generated by removing B2M to inhibit T cell-mediated rejection, and by overexpression of HLA-E trimer
to avoid the natural killer (NK) cell-mediated lysis of transplanted cells. The investigators will then use in vitro
and in vivo assays to characterize programmed beta cells. For in vitro experiments, the investigator will
perform glucose stimulated insulin secretion assay. For in vivo assays, the investigator will use the NRG Akita
mice to test whether programmed beta cells can reverse diabetes in vivo. The investigator will also use
humanized NSG mice to study whether programmed beta cells from universal donor hiPSCs exhibit immune
evasive properties as compared to cells generated from normal hiPSCs.
Status | Finished |
---|---|
Effective start/end date | 5/1/23 → 4/30/25 |
Funding
- National Institute of Diabetes and Digestive and Kidney Diseases: $224,570.00
- National Institute of Diabetes and Digestive and Kidney Diseases: $240,478.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.